North America CAR T-Cell Therapy Market

1
North America's CAR T-Cell Therapy Market A
Comparative Analysis of Kite Pharma and Novartis
The North America CAR T-Cell Therapy Market has
experienced significant growth, driven by
advancements in immunotherapy and personalized
medicine. In 2023, the market was valued at
approximately USD 1.5 billion, with projections
indicating continued expansion in the coming
years. Two key players in this sector are Kite
Pharma, a subsidiary of Gilead Sciences, and
Novartis. Both companies have made notable
strides in CAR T-cell therapy, offering
innovative treatments for various cancers.
Company Profiles and Product Lines Understanding
the backgrounds and product offerings of Kite
Pharma and Novartis provides insight into their
positions within the North America CAR T-cell
therapy market.
2

• Kite Pharma (Gilead Sciences)
• Establishment Year 2009
• Headquarters Santa Monica, California
• Key Products
• Yescarta (axicabtagene ciloleucel) Approved for
  the treatment of certain types of large B-cell
  lymphoma.
• Tecartus (brexucabtagene autoleucel) Approved
  for mantle cell lymphoma and acute lymphoblastic
  leukemia.
• Kite Pharma specializes in developing CAR T-cell
  therapies targeting hematologic malignancies.
  Their focus on B-cell lymphomas has positioned
  them as a leader in this niche market.
• Novartis
• Establishment Year 1996
• Headquarters Basel, Switzerland
• Key Product Kymriah (tisagenlecleucel) Approved
  for treating acute lymphoblastic leukemia (ALL)
  in pediatric and young adult patients, as well as
  certain types of non-Hodgkin lymphoma.
• Novartis was the first to receive FDA approval
  for a CAR T-cell therapy, marking a significant
  milestone in cancer treatment. Kymriah's approval
  for both pediatric ALL and non-Hodgkin lymphoma
  showcases Novartis's commitment to expanding CAR
  T-cell applications.
• Financial Performance and Market Share
• Analyzing the financial performance of these
  companies sheds light on their impact within the
  CAR T-cell therapy market.

3
CAR T-cell therapies, approached 2 billion in
sales, reflecting a substantial growth and
establishing Kite as a leading provider of CAR
T-cell therapies globally. Novartis Novartis
reported total revenues of 50.3 billion in 2024,
a 10.85 increase from the previous year. This
growth was driven by strong performances across
various therapeutic areas, including oncology.
While specific revenue figures for Kymriah were
not disclosed, the therapy has contributed to
Novartis's oncology portfolio, reflecting the
company's commitment to innovative cancer
treatments.
Strategic Developments and Collaborations

• Both Kite Pharma and Novartis have engaged in
  strategic initiatives to enhance their CAR T-
  cell therapy offerings.
• Kite Pharma (Gilead Sciences)
• Manufacturing Expansion Kite has invested in
  manufacturing facilities, including a site in
  Amsterdam, to meet the growing demand for CAR
  T-cell therapies. This expansion aims to reduce
  production timelines and improve patient access.
• Acquisition In 2023, Kite completed the
  acquisition of Tmunity Therapeutics, aiming to
  enhance its cell therapy pipeline and
  manufacturing capabilities.
• Novartis
• T-Charge Platform Novartis has been developing
  its T-Charge platform, a next- generation CAR
  T-cell technology designed to enhance efficacy
  and safety. Early clinical trials using this
  platform, specifically with therapies YTB323
  (targeting CD19) and PHE885 (targeting BCMA),
  have shown promising results.
• Partnerships Novartis has partnered with major
  research institutions to accelerate the
  development of its CAR T-cell therapies, aiming
  to expand their applications to solid tumors.

4
Comparison Table Kite Pharma vs. Novartis
Aspect Kite Pharma (Gilead Sciences) Novartis
Establishment Year 2009 1996
Headquarters Santa Monica, CA Basel, Switzerland
Key CAR T-Cell Products Yescarta, Tecartus Kymriah
2023 CAR T-Cell Revenue 2 billion Not disclosed
Strategic Focus Hematologic malignancies Broad oncology applications
Recent Developments Acquisition of Tmunity Therapeutics manufacturing expansion Development of T-Charge platform research partnerships
Conclusion
The North America CAR T-Cell Therapy Market
continues to evolve, with Kite Pharma and
Novartis at the forefront. Kite's focus on
hematologic malignancies and significant
investment in manufacturing capabilities have
solidified its position as a leader in the CAR
T-cell therapy market. Novartis's pioneering
approval of Kymriah and ongoing development of
next-generation CAR T-cell platforms demonstrate
its commitment to expanding the therapeutic
potential of CAR T-cell therapies. As both
companies advance their research and strategic
initiatives, the CAR T-cell therapy landscape is
poised for continued growth and
innovation. Download the Sample Report to
explore key market insights.

• Relatable Reads
• Global Cargo Global Cargo Drones Market
  Innovations and Market Opportunities
• USA Packaged Food Market Demand Drivers and
  Emerging Trends